Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2018-01-09 Regulatory Filings
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the completion of patient enrollment for a Phase 2a clinical trial. It provides details on the study, the drug candidate (GNbAC1), and the company's background. Since this is a general corporate announcement regarding operational progress (clinical trial milestones) that does not fit into specific financial reporting categories like 10-K, IR, or ER, it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2018-01-09 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the completion of patient recruitment for a Phase 2a clinical trial. It provides details on the study, the drug candidate (GNbAC1), and the company's background. It does not constitute a full financial report, an investor presentation, or a regulatory filing of a specific form type. In the context of financial document classification, press releases regarding clinical trial milestones are categorized as general regulatory announcements or corporate news updates, which fall under the 'RNS' (Regulatory Filings) category.
2018-01-09 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Transaction in Own Shares Classification · 1% confidence The document is a press release detailing the status of a liquidity contract (share buyback/liquidity provision) for GeNeuro as of December 31, 2017. It lists the number of shares and cash balance held in the liquidity account. This type of disclosure regarding the company's own share transactions and liquidity management falls under the 'Transaction in Own Shares' category.
2018-01-03 French
Share buybacks / Liquidity contracts Information related to liquidity contracts
Regulatory Filings Classification · 1% confidence The document is a short press release (under 5,000 characters) detailing the status of a liquidity contract (share and cash balances) as of a specific date. It does not constitute a full financial report, but rather a periodic disclosure of market-making activities. Since it does not fit into specific categories like share buybacks (POS) or major shareholding notifications (MRQ), and serves as a general regulatory update regarding the company's liquidity account, it is best classified as a general regulatory filing.
2018-01-03 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the completion of the final patient visit in a Phase 2b clinical trial (CHANGE-MS) and the subsequent triggering of a milestone payment from their partner, Servier. It provides details on the clinical trial status, the financial impact of the milestone, and background information on the company's research. This fits the definition of a Regulatory Filing (RNS) as it is a corporate announcement regarding operational and financial milestones that does not fall into more specific categories like Earnings Release or Annual Report.
2017-12-21 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing a milestone payment of €12 million from their partner Servier following the completion of a clinical trial phase. It details the clinical study progress, the financial impact of the milestone, and provides background on the company's research. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. It is a corporate announcement regarding business operations and financial milestones, which falls under the Regulatory Filings (RNS) category as a general corporate announcement.
2017-12-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.